Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

MANILA, Philippines — The country’s total outstanding debt climbed to a fresh high of P16.68 trillion as of end-March, 12 percent higher than last year’s P14.93 trillion, the Bureau of the ...

State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer Doxorubicin plus trabectedin followed by trabectedin maintenance showed a survival advantage ...

Among the new phase 3 starts are CDK4 inhibitor atirmociclib as a second-line therapy for hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell ...

Breast cancer is caused by the development of malignant cells in the breast. The malignant cells originate in the lining of the milk glands or ducts of the breast (ductal epithelium). Breast ...

In early-stage estrogen receptor-positive (ER + ) breast cancer, resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) often involve a shift away from estrogen-driven proliferation. The ...

MANILA – The Bureau of the Treasury (BTr) assured Wednesday that the national government’s (NG) total outstanding debt remains manageable, standing at PHP16.68 trillion as of end-March 2025. In a ...

In this issue, Yi and colleagues demonstrate therapeutic synergy for combined PARP and CDK4/6 inhibition and identify MYC status as a determinant of sensitivity to combined PARP and CDK4/6 inhibition ...